Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.

ABSTRACT:

SUBMITTER: Spencer SJ 

PROVIDER: S-EPMC10394221 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature